APA

Jilkova Z. M., Kuyucu A. Z., Kurma K., Ahmad Pour S. T., Roth G. S., Abbadessa G., Yu Y., Schwartz B., Sturm N., Marche P. N., Hainaut P. & Decaens T. (2018). Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. : Oncotarget.

Chicago

Jilkova Zuzana Macek, Kuyucu Ayca Zeybek, Kurma Keerthi, Ahmad Pour Séyédéh Tayébéh, Roth Gaël S, Abbadessa Giovanni, Yu Yi, Schwartz Brian, Sturm Nathalie, Marche Patrice N, Hainaut Pierre and Decaens Thomas. 2018. Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. : Oncotarget.

Harvard

Jilkova Z. M., Kuyucu A. Z., Kurma K., Ahmad Pour S. T., Roth G. S., Abbadessa G., Yu Y., Schwartz B., Sturm N., Marche P. N., Hainaut P. and Decaens T. (2018). Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. : Oncotarget.

MLA

Jilkova Zuzana Macek, Kuyucu Ayca Zeybek, Kurma Keerthi, Ahmad Pour Séyédéh Tayébéh, Roth Gaël S, Abbadessa Giovanni, Yu Yi, Schwartz Brian, Sturm Nathalie, Marche Patrice N, Hainaut Pierre and Decaens Thomas. Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. : Oncotarget. 2018.